Article
Plasma cell-free tumor DNA, PIK3CA and TP53 mutations predicted inferior endocrine-based treatment outcome in endocrine receptor-positive metastatic breast cancer.
Breast cancer research and treatment - 1 Oct 2023
Chen Tom Wei-Wu, Hsiao Wen, Dai Ming-Shen, Lin Ching-Hung, Chang Dwan-Ying, Chen I-Chun, Wang Ming-Yang, Chang Shu-Han, Huang Shu-Min, Cheng Ann-Lii, Wu Ko-Wen, Tan Kien Thiam, Lu Yen-Shen
Abstract excerpt
PURPOSE: How to factor both tumor burden and oncogenic genomic mutations as variables to predict the outcome of endocrine-based therapy (ET) in ER-positive/HER2-negative metastatic breast cancer patients (MBC) remains to be explored. METHOD: Blood samples prospectively collected from 163 ER-positive/HER2-negative female MBC patients, before ET, were used for cell-free tumor DNA (cfDNA) analysis. cfDNA was...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.